Brainstorm Cell Therapeutics
Petah Tikva, New York, United States · Biotechnology, Health Care, research
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote
Key facts
- Headquarters
- Petah Tikva, New York, United States
- Employees
- 27
- Industries
- Biotechnology, Health Care, research
- Status
- Public (BCLI)
- Website
- brainstorm-cell.com
- Company page
Recent activity at Brainstorm Cell Therapeutics
- : Brainstorm Cell Therapeutics Secures $1 Million in Private Placement Funding
- : SEC 8-K (1.01): On February 9, 2026, Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement with an accredited investor to sell shares of its common stock and pre-funded warrants in a private placement totaling $1,000,000. The transaction will be executed in two closings, with $500,000 at each closing. The purchase price per share is set at $0.60, and the pre-funded warrants are priced at $0.60 less $0.0005, with an exercise price of $0.00005 per share. This agreement indicates a strategic move to raise capital and potentially indicates confidence in the company's future growth prospects.
- : Brainstorm Cell Therapeutics Secures $155,000 in Funding
- : SEC 8-K (1.01): On October 31, 2025, Brainstorm Cell Therapeutics Inc. entered into a securities purchase agreement with Vanquish Funding Group Inc., issuing a promissory note valued at $182,400, which includes an original issue discount of $22,400. The company received $155,000 after deducting combined legal and due diligence fees of $5,000. In case of default, the note can be converted into common stock at a 35% discount based on the stock's value over the past 10 trading days, and it accrues interest at a rate of 12%. This financing arrangement provides immediate capital to support the company's operations, while also allowing for potential dilution of shareholder equity if the note is converted into stock.
- : BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
- : BrainStorm Cell Therapeutics Inc. Appoints Hartoun Hartounian Ph.D. as EVP and COO
- : BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
- : BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2026 | Post-IPO Equity | $1.0M |
| Nov 2025 | Funding Round | $155K |
| Jun 2018 | Venture | Undisclosed |
Leadership
- Uri Yablonka, Executive Director & EVP, Chief Business Officer
- Malcolm Taub, Director
- Polverino, Director
- Chen Schor, Director
- Almenoff, Director
- Arbel, Director
- Uri Yablonka, Executive Officer, Director
- Haro Hartounian, Chief Operating Officer
- Chaim Lebovits, Chief Executive Officer
- Bob Dagher, Executive Vice President
- Arturo Araya, Executive Officer
- Eyal Rubin, Executive Officer
Verified email and direct lines for Brainstorm Cell Therapeutics’s decision-makers are on Fundz. See plans
Brainstorm Cell Therapeutics in the news
- BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - PR Newswire (Jun 02, 2026)
- BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance (Aug 14, 2026)
- BrainStorm levels up, bringing on former FDA leader Peter Pitts for new ALS bid - BioSpace (Jun 02, 2026)
- BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire (May 15, 2026)
- BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - PR Newswire (May 28, 2026)
- FDA Grants Meeting With BrainStorm Cell Therapeutics on ALS Therapy NurOwn - NeurologyLive (Nov 21, 2023)
- BrainStorm Cell Therapeutics Partners to Provide Public Access to Biospecimens from NurOwn’s Phase 3 ALS Study - ALS Network (Jan 10, 2023)
- FDA AdComm Votes Down BrainStorm Cell Therapeutics’ ALS Cell Therapy NurOwn - CGTLive® (Sep 27, 2023)
Companies similar to Brainstorm Cell Therapeutics
- BioLineRx Ltd · Biotechnology, Health Care, research, Therapeutics
- Nuvig Therapeutics · Biotechnology, Health Care, research, Therapeutics
- Draig Therapeutics · Biotechnology, Health Care, research, Therapeutics
- Cantargia AB · Biotechnology, Health Care, research, Therapeutics
- Corner Therapeutics · Biotechnology, Health Care, research, Therapeutics
About Brainstorm Cell Therapeutics: questions and answers
What does Brainstorm Cell Therapeutics do?
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote
Where is Brainstorm Cell Therapeutics headquartered?
Brainstorm Cell Therapeutics is headquartered in Petah Tikva, New York, United States.
How many employees does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has about 27 employees.
Has Brainstorm Cell Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Brainstorm Cell Therapeutics. The most recent, Post-IPO Equity of $1.0M, was in Feb 2026.
Who leads Brainstorm Cell Therapeutics?
Chaim Lebovits is a Chief Executive Officer at Brainstorm Cell Therapeutics.
What is the latest news on Brainstorm Cell Therapeutics?
On Feb 13, 2026, Brainstorm Cell Therapeutics Secures $1 Million in Private Placement Funding
Is Brainstorm Cell Therapeutics a public company?
Yes. Brainstorm Cell Therapeutics is publicly traded under the ticker BCLI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy